Loading
BridgeBio Oncology Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$232.9M
BridgeBio Oncology Therapeutics, Inc.: what insiders have been doing
BridgeBio Oncology Therapeutics, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 18 October 2025 and 18 October 2026, 6 insiders published 17 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 17 filings here.
Over the last twelve months, not one insider purchase of BridgeBio Oncology Therapeutics, Inc. stock was filed. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
24
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.91
Analyst consensus
11 analysts1.33/5
US$15.00Target US$24.55(+745%)US$50.00
Income statement
EBITDA-US$145.2M
Net income-US$134M0.0% margin
Valuation
PER (forward)-1.1x
P/Book0.7x
Beta0.65
Balance sheet & cash
Market capUS$232.9M
Total debtUS$2.8M
Free Cash Flow-US$114.5M
Debt / Equity1%
Profitability & ownership
ROE-81.9%
ROA-47.1%
% insiders27.1%
% institutions71.1%
Last declaration on 5 October 2026
Declarations24 total
343 shares@ US$3.940.0004% mcap33.6% of flowCommon StockSEC:0001193125-26-414131:0
1,047 shares@ US$3.940.0013% mcap33.6% of flowCommon StockSEC:0001193125-26-414127:0
2,692,459 shares0Common StockSEC:0001213900-26-075538:1
1,047 shares@ US$7.800.0026% mcap100.0% of flowCommon StockSEC:0001193125-26-296501:0
343 shares@ US$7.800.0008% mcap100.0% of flowCommon StockSEC:0001193125-26-296503:0
1,704,862 shares0Common StockSEC:0001213900-26-075538:2
130,865 shares0Common StockSEC:0001213900-26-075538:3
4,528,186 shares0Common StockSEC:0001213900-26-075538:0
23,330 shares0Common StockSEC:0001193125-26-104384:0
46,670 shares0Common StockSEC:0001193125-26-104379:0
784,720 sharesCommon StockSEC:0001193125-25-241634:0
4,172,126 sharesCommon StockSEC:0001213900-25-075305:0
30,000 sharesCommon StockSEC:0001213900-25-074375:0
30,000 sharesCommon StockSEC:0001213900-25-074368:0
30,000 sharesCommon StockSEC:0001213900-25-074364:0
509,000 shares@ US$10.00100.0% of flowClass A Ordinary SharesSEC:0001213900-24-013530:0
509,000 shares@ US$10.00100.0% of flowClass A Ordinary SharesSEC:0001213900-24-013534:0
24 of 24 declarations
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for patients with cancer. It specializes in targeted therapies and genetics-based approaches.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
